Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis [1] . AML is thought to be initiated and maintained by a rare population of leukemia stem cells (LSCs) or leukemia-initiating cells (LICs) that have acquired the capacity for self-renewal and is blocked in their ability to differentiate by the accumulation of a series of mutations and/or epigenetic changes [2, 3] . Clinical studies show that LICs are resistant to conventional chemotherapy and/or targeted therapies [3] . Thus, there is an unmet need to elucidate the molecular mechanisms governing LIC selfrenewal and develop novel therapeutic approaches that can target LICs and improve leukemia treatment [3] .
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Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis [1] . AML is thought to be initiated and maintained by a rare population of leukemia stem cells (LSCs) or leukemia-initiating cells (LICs) that have acquired the capacity for self-renewal and is blocked in their ability to differentiate by the accumulation of a series of mutations and/or epigenetic changes [2, 3] . Clinical studies show that LICs are resistant to conventional chemotherapy and/or targeted therapies [3] . Thus, there is an unmet need to elucidate the molecular mechanisms governing LIC selfrenewal and develop novel therapeutic approaches that can target LICs and improve leukemia treatment [3] . The tumor suppressor p53 is a stress response protein that regulates a large number of genes in response to a variety of cellular insults, including oncogene activation, DNA damage, and inflammation [4] . These signals activate p53 primarily through post-translational modifications that result in augmented levels of p53 protein and transactivation activity [4] . Activated p53 suppresses cellular transformation mainly by inducing growth arrest, apoptosis, DNA repair, and differentiation in damaged cells [4] . Accordingly, p53 function is always compromised in tumor cells, usually as a result of somatic mutations and deletions, which occur in approximately half of all human cancers [5] . The TP53 gene encodes the tumor suppressor p53. The frequency of TP53 mutations in AML is~10%. However, in AML with complex karyotype, the frequency of TP53 mutations and/or deletions is almost 70% [6] . While TP53 mutations confer drug resistance and poor prognosis in AML, the role of mutant p53 in the initiation and progression of AML is largely unknown [6, 7] .
We have been investigating the role of tumor suppressor p53 in normal and malignant hematopoiesis. We found that wild-type p53 maintains HSC quiescence and inhibits HSC self-renewal [8] . Codon 248 of p53 is frequently mutated in AML and p53 R248W has been shown to be a gain-of-function (GOF) mutant in human cancer cells as well as in animal models [6, 7, 9] . We recently reported that p53 R248W enhances HSC self-renewal in steady state and promotes HSC expansion following genotoxic stresses [10] . Of note, homozygous p53 −/− and p53 R248W/R248W mice develop lymphoid tumors, including lymphoma and thymoma, but not myeloid malignancies [9] , suggesting that expression of mutant p53 is not sufficient for inducing myeloid leukemia in mice. This has led to a search for potential second hits that cooperate with mutant p53 in the pathogenesis of myeloid malignancies, primarily focused on using mouse models.
While coexisting mutations with TP53 mutations in AML are limited [6, 7] , previous studies indicate that TP53 mutations co-occur with AML driver mutations in oncogenic signaling molecules, such as FMS-like tyrosine kinase receptor-3 (FLT3) [11] . Mutations in FLT3 have been identified in myeloid malignancies, including myeloproliferative neoplasms (MPN) and AML [12] . Internal tandem duplications in the juxtamembrane domain (FLT3-ITD) and mutations in the activating loop of FLT3 (FLT3-TKD) are seen in 30-35% of AML patients [12] . Both ITD and TKD mutations of FLT3 lead to constitutive activation of the tyrosine kinase, promoting proliferation, and survival of leukemic blasts [12] . Given that expression of FLT3-ITD in the hematopoietic compartment results in MPN in mice and that FLT3-ITD impairs HSC self-renewal in vivo [13] , we reasoned that mutant p53 might synergize with FLT3-ITD in driving the development of myeloid leukemia through enhancing LIC self-renewal.
To test this hypothesis, we generated p53 R248W/+ FLT3 ITD/+ mice and monitored overall survival and tumor development of these mice. We observed that both FLT3 ITD/+ and p53 R248W/+ FLT3 ITD/+ mice have decreased life span compared with p53 +/+ mice (Fig. 1a) . Some p53 R248W/+ mice develop myelodysplastic syndromes (MDS) with age and other p53 R248W/+ mice developed lymphoma and sarcoma based upon pathological analysis of the bone marrow (BM), spleen, liver, and peripheral blood (PB) (SC and YL, unpublished data). However, the majority of p53 reduction and almost total absence of the white pulp in some cases and increased red pulp area with increased extramedullary hematopoiesis (Fig. 1c) . These features appeared in conjunction with hepatosplenomegaly, variable leukocytosis and overproduction of myeloid cells in the bone marrow, spleen, and peripheral blood (Fig. 1c) . We noted that the bone marrow cellularity decreased as splenomegaly increased, consistent with increased extramedullary hematopoiesis. Notably,~25% of p53 R248W/+ FLT3 ITD/+ mice developed chronic myeloid leukemia (CML) [14] . Upon necropsy, mice with CML displayed severe splenomegaly, and some also displayed hepatomegaly. Morphological analysis of peripheral blood smears revealed increased myeloid cells with dysplastic features (Fig. 1c) . The bone marrow cellularity varied from hypocellular to hypercellular among animals. Increased number of myeloid cells (blast to immature myeloid cells) was observed in the bone marrow with extensive spread of myeloid elements in the spleen and in a few livers (Fig. 1c) . While p53
ITD/+ mice showed marked splenomegaly compared with p53 +/+ and FLT3 ITD/+ mice (Fig. 1d) , this is not likely due to CML development as majority of doublemutant mice developed MPN (Fig. 1b, c) .
Given that patients with homozygous FLT3-ITD mutations have a more severe disease compared with those with heterozygous FLT3-ITD mutations [11, 12] Figure S1a ).
Interestingly,~30% of the p53 R248W/+ FLT3 ITD/ITD transplanted animals developed CML ( Figure S1b ), similar to that seen in p53 R248W/+ FLT3 ITD/+ animals (Fig. 1b) Figure S2b ). These findings suggest that the effects of mutant p53 and FLT3-ITD on myeloid progenitor cell expansion appears additive. However, the number of common lymphoid progenitors (CLPs) was comparable among four group of mice ( Figure S2c ).
FLT3 mutations have been shown to enhance the proliferation of hematopoietic stem and progenitor cells [13] . BM cells (Fig. 2a) , suggesting that expanded myeloid progenitors in p53 R248W/+ FLT3 ITD/+ mice are functional in vitro.
To examine the impact of mutant p53 on HSCs in vivo, we performed serial competitive bone marrow transplantation assays. We transplanted 5 × 10 5 donor BM cells (p53 ITD/+ BM cells (Fig. 2b) . We then killed the recipient mice and examined the frequency of donor-derived hematopoietic stem and progenitor cells in their bone marrow. We found increased number of donor-derived LSKs in the BM of recipient mice repopulated with p53 R248W/+ BM cells compared with that of the p53 +/+ and ITD/+ BM cells (Fig. 2c) . These findings suggest that mutant p53 may promote leukemic transformation through enhancing LIC self-renewal.
To examine the impact of mutant p53 on oncogenic signaling pathways, we performed western blot analysis on macrophage progenitor cells derived from p53 (Fig. 2d) . Further, expressing FLT3-ITD in a mutant p53 background enhances activated ERK levels, but slightly decreases activated FAK and STAT5 levels (Fig. 2d) . We found increased levels of FLT3 in p53 R248W/+ FLT3 ITD/+ macrophage progenitor cells ( Figure S3c) . Thus, expressing FLT3-ITD in a mutant p53 background has no effect on FLT3-ITD-induced activation of signaling pathways. However, ERK inhibitor treatment decreased the replating potential of p53 R248W/+ , FLT3 ITD/+ , and p53 R248W/+ FLT3 ITD/+ bone marrow cells ( Figure S3d ). These findings suggest that mutant p53 and FLT3-ITD may function through different signaling pathways in the pathogenesis of hematological malignancies. In future, we will elucidate the mechanisms by which mutant p53 upregulates FLT3 in HSPCs. 
